HEPATIC STELLATE CELLS: DRIVERS OF LIVER FIBROSIS
When there is repeated or chronic injury to the liver, the attempts at repair go awry, resulting in fibrosis. Emerging antifibrotic therapies aim to prevent or halt fibrotic induction in hepatic stellate cells (HSCs), the major drivers of this disease.
Our Ready-2-Go Assay Service assesses the effects of your test articles with quantitative, phenotypic readouts to measure fibrotic progression in HSCs.
KEY FEATURES
Uses human, primary HSCs
Get readouts that characterize intracellular and extracellular fibrosis indicators
Only 6-8 weeks from assay to report
Option to bundle R2G Services or transition to Custom Services
AVOID SPECIES DIFFERENCES WITH PRIMARY, HUMAN HSCs
The use of animal models or immortalized cell lines limits clinical translatability. We use primary, human HSCs to circumvent the animals-to-human, translational gap, saving you time and money in your drug-discovery efforts.
RELATED READY-2-GO SERVICES
Browse related Ready-2-Go assay offerings. For custom assays, check out our Custom Services.
R2G CELL HEALTH
Multiplexed readouts of proliferation, viability, and apoptosis.
Learn more
R2G MITOCHONDRIAL HEALTH
Screen for changes in mitochondrial membrane potential.
Learn more
R2G LUNG FIBROSIS
Fibrotic induction and inhibition are measured in lung fibroblasts.
Learn more